News

Calidi Biotherapeutics Prepares for Exciting Investor Conference

Calidi Biotherapeutics Prepares for Exciting Investor Conference

Calidi Biotherapeutics to Present at a Major Conference

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a pioneering biotech company focused on developing innovative targeted therapies, is excited to announce its involvement in an important upcoming investor conference. This prominent event, the H.C. Wainwright 27th Annual Global Investment Conference, will take place at a prestigious venue, setting the stage for meaningful interactions between the company’s leadership and valued investors.

What to Expect at the Conference

During this conference, which spans several days, Calidi's Chief Executive Officer, Dr. Eric Poma, will introduce the company's path-breaking discoveries and strategic vision. He has recorded a presentation that will be available for on-demand viewing, beginning ahead of the conference. This presentation will delve into the unique capabilities of Calidi's RedTail platform, characterized by its innovative approach to virotherapy. This technology is designed to protect therapeutic viruses from immune responses, enhancing their efficacy in delivering genetic medicines directly to cancerous sites.

Highlighting the RedTail Platform

Dr. Poma’s presentation is anticipated to shed light on how the RedTail platform effectively induces tumor lysis while ensuring that therapeutic agents are able to reach targeted metastatic areas through an advanced delivery method. This advancement is particularly noteworthy as it has the potential to transform cancer treatment by engaging the body’s immune system to combat malignancies more effectively.

One-on-One Investor Meetings

Another exciting aspect of the conference is that Dr. Poma will also be available for one-on-one meetings with registered investors. These personalized interactions provide a unique opportunity for interested parties to discuss insights into Calidi's strategic initiatives, answer queries, and explore potential collaborations.

About Calidi Biotherapeutics

Calidi Biotherapeutics is at the forefront of immuno-oncology, focused on creating therapies that aim to deliver genetic medicines directly to challenging areas of disease. With the proprietary RedTail platform, Calidi employs an engineered oncolytic virus that is designed for systemic action and specifically targets metastatic cancer sites. This capability allows the virus to evade the immune system, effectively administering therapeutic strategies to combat severe cancers like non-small cell lung cancer and ovarian cancer, among others.

Currently, Calidi is conducting IND-enabling studies on its lead candidate, aimed at addressing significant unmet medical needs in oncology. The company also explores the development of localized virotherapies, which are in the clinical stage, focusing on injectable treatment options for specific cancer indications.

Learn More About Calidi

Calidi Biotherapeutics is based in San Diego, California, and is committed to advancing the field of targeted cancer therapies. For those seeking further information, the company encourages visits to their official website for updates regarding their research and development efforts.

Frequently Asked Questions

What is the primary focus of Calidi Biotherapeutics?

Calidi Biotherapeutics specializes in developing targeted therapies to deliver genetic medicines directly to difficult-to-reach sites of cancerous diseases.

How does the RedTail platform work?

The RedTail platform utilizes an engineered oncolytic virus that protects itself from immune clearance, enabling effective delivery of therapeutic agents to tumor sites.

Who will be presenting at the H.C. Wainwright conference?

Dr. Eric Poma, the CEO of Calidi Biotherapeutics, will be presenting at the conference and available for personalized investor meetings.

What types of cancer are being targeted by Calidi's therapies?

Calidi's therapies predominantly target non-small cell lung cancer, ovarian cancer, and other types of tumors with significant medical need.

Where can I find more information about Calidi Biotherapeutics?

Further information can be accessed through their official website, which provides updates on their innovative therapies and company news.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RealNex Navigator Upgrades Unveil Vast CRE Capabilities

Updated Category News Views 3

The Dawn of a New Navigator for CRE RealNex is unleashing a storm of enhancements to its Navigator platform, shaking up the commercial real estate (CRE) scene. Their latest upgrades are setting a new precedent for how brokers use technology to sharpen their game, handle transactions, and strategize in a market that never sleeps. Diving Deep into the Latest Upgrades First...

Continue Reading
Monib Zirvi's Dermatology Excellence Honored in 2026

Updated Category News Views 6

Trailblazer in Dermatology Recognized Again Fancy yourself a star in dermatology? Well, take notes from Dr. Monib A. Zirvi. The guy just got his due recognition from Marquis Who's Who for his sizable contributions to dermatology and research. For someone who's been at this game for over two decades, Zirvi doesn't just glide by on old merits. He's the real deal, and his...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 3

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading
Helio Fred Garcia Honored by Diversity Action Alliance

Updated Category News Views 4

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Continue Reading
EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Updated Category News Views 6

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 4

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
Unpacking RAGEism: Power Dynamics in U.S. Policies

Updated Category News Views 2

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Continue Reading
Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 3

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 2

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading

Top 5 Most Recently Viewed Articles

Enhanced Water Radar Sensor Introduced for Flood Prevention

Updated Category News Views 90

Introduction of the New Water Level Radar Sensor As climate-related challenges intensify, managing water resources effectively has become more critical than ever. With increasing rainfall in some areas while others face declining water levels, the need for accurate monitoring technology is paramount. KISTERS, a pioneering climate tech developer, has launched the HyQuant...

Continue Reading
Navigating the Implications of Budget Deficits on Markets

Updated Category News Views 203

Federal Budget Deficit: An Economic Overview The federal budget deficit is a critical factor in the economic landscape, impacting not only domestic but also global markets. At its core, a federal budget deficit occurs when government expenditures exceed revenues over a fiscal year, usually making up the gap through borrowing. While this practice can be beneficial in...

Continue Reading
Purple Biotech Secures $2.8 Million Through Direct ADS Offering

Updated Category News Views 89

Purple Biotech's Recent ADS Offering Overview Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is making headlines with a recent announcement about a significant financial maneuver. The company, recognized for its innovative approaches in developing therapies to combat tumor immune evasion and drug resistance, has entered into a definitive agreement to issue 472,668 American...

Continue Reading
Hexagon Strengthens Public Safety with CONET Communications Deal

Updated Category News Views 312

Strengthening Public Safety Efforts Hexagon AB recently announced an exciting agreement to acquire the Unified Communications Radio Suite (UCRS) from CONET Communications GmbH, part of the broader CONET Group. This strategic move aims to enhance their public safety platform, reinforcing Hexagon's commitment to ensuring effective communication in emergency situations. What...

Continue Reading
Hyatt Hotels Report Q4 Earnings, Plans Expansion for 2025

Updated Category News Views 327

Hyatt Hotels Faces Earnings Challenges Hyatt Hotels Corporation (NYSE: H) shares have seen a notable decline recently, as the company reported fourth-quarter adjusted earnings of only 42 cents per share. This figure fell short of analyst expectations, which had anticipated earnings of 78 cents. Additionally, the company's quarterly sales totaled $1.602 billion, missing...

Continue Reading